Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were treated with a combination of radiotherapy and chemotherapy (and no surgery) for locally advanced cervical cancer, classified as stage Ib to IVb under the FIGO staging system.
- People who are 18 years of age or older.
- People who have had at least 2 years of follow-up care after completing their treatment.
- People for whom the original tissue sample (biopsy taken before treatment began) is still available.
- People who have not previously indicated that they do not wish to take part in research studies.
- People who are covered by a health insurance scheme.
Who may not be able to join:
- People who are under a court-ordered legal protection measure, such as guardianship or a similar arrangement that limits their legal decision-making capacity.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexandre TAYART de BORMS, Interne, Nîmes University Hospital
Phone: +334.34.03.46.69
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prognostic role of overexpression of XIAP on the rate of local recurrence in patients treated for locally advanced cervical cancer.; Prognostic role of overexpression of XIAP on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer.; Prognostic role of overexpression of cIAP1 on the rate of local recurrence in patients treated for locally advanced cervical cancer.; Prognostic role of overexpression of cIAP1 on the rate of local recurrence at 24 months follow-up in patients treated for locally advanced cervical cancer.; Prognostic role of o...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.